摘要
癌症作为一种遗传性疾病是全世界死亡的主要原因之一。传统抗癌选项如化疗和/或放射疗法都有自己的缺点,目前在大多数情况下不能提供治愈。迫切需要拥有更少的副作用更有效的治疗策略。寡核苷酸适配子,也称为化学抗体,是单股DNA或RNA分子,可以绑定到目标分子具有高亲和力和特异性。这样的特异性结合位点绑定寡核苷酸适配子的能力促进外源核酸的传递和与病基因的互动。因此,除了经典的治疗方案,适配子指导的基因治疗已成为一个有前途的抗癌策略。寡核苷酸适配子可以直接提供抗癌核酸,如小干扰RNA、微RNA、antimicroRNA和小发夹RNA、癌细胞或作为靶向配体来指导纳米粒子核酸治疗。本文综述近年来在适配子指导的基因疗法治疗肝细胞癌和其他类型的癌症,揭示这一新型的潜在癌症靶向基因治疗的方法。
关键词: 适配体,基因治疗,微小核糖核酸,核糖核酸干扰,癌症,肝癌
Current Gene Therapy
Title:Aptamer-Mediated Cancer Gene Therapy
Volume: 15 Issue: 2
Author(s): Dongxi Xiang, Sarah Shigdar, Greg Qiao, Shu-Feng Zhou, Yong Li, Ming Q. Wei, Liang Qiao, Hadi Al. Shamaileh, Yimin Zhu and Conglong Zheng, Chunwen Pu and Wei Duan
Affiliation:
关键词: 适配体,基因治疗,微小核糖核酸,核糖核酸干扰,癌症,肝癌
摘要: Cancer as a genetic disorder is one of the leading causes of death worldwide. Conventional anticancer options such as chemo- and/or radio-therapy have their own drawbacks and could not provide a cure in most cases at present. More effective therapeutic strategies with less side effects are urgently needed. Aptamers, also known as chemical antibodies, are single strand DNA or RNA molecules that can bind to their target molecules with high affinity and specificity. Such site-specific binding ability of aptamers facilitates the delivery and interaction of exogenous nucleic acids with diseased genes. Thus, aptamer-guided gene therapy has emerged as a promising anticancer strategy in addition to the classic treatment regimen. Aptamers can directly deliver anti-cancer nucleic acids, e.g. small interfering RNA, micro RNA, antimicroRNA and small hairpin RNA, to cancer cells or function as a targeting ligand to guide nanoparticles containing therapeutic nucleic acids. This review focuses on recent progress in aptamer-mediated gene therapy for the treatment of hepatocellular carcinoma and other types of cancers, shedding light on the potential of this novel approach of targeted cancer gene therapy.
Export Options
About this article
Cite this article as:
Dongxi Xiang, Sarah Shigdar, Greg Qiao, Shu-Feng Zhou, Yong Li, Ming Q. Wei, Liang Qiao, Hadi Al. Shamaileh, Yimin Zhu and Conglong Zheng, Chunwen Pu and Wei Duan , Aptamer-Mediated Cancer Gene Therapy, Current Gene Therapy 2015; 15 (2) . https://dx.doi.org/10.2174/1566523214666141224095105
DOI https://dx.doi.org/10.2174/1566523214666141224095105 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery
Current Cancer Drug Targets Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Biomarker Discovery and Translation in Metabolomics
Current Metabolomics Accelerated Cytotoxicity Mechanism Screening Using Drug Metabolising Enzyme Modulators
Current Drug Metabolism Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies Hypoxia and Radiation Therapy: Past History, Ongoing Research, and Future Promise
Current Molecular Medicine T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
Current Cancer Drug Targets Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry Advances in the Integration of Drug Metabolism into the Lead Optimization Paradigm
Mini-Reviews in Medicinal Chemistry Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets Targeting Tumor Angiogenesis in Gastrointestinal Malignancies
Current Angiogenesis (Discontinued) Development of Specific New ELISA for Bioanalysis of Cetuximab: A Monoclonal Antibody Used for Cancer Immunotherapy
Current Pharmaceutical Analysis Hepatocytes as Cytotoxic Effector Cells
Current Immunology Reviews (Discontinued) Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Computational Analysis of Domains Vulnerable to HPV-16 E6 Oncoprotein and Corresponding Hot Spot Residues
Protein & Peptide Letters